Table 3 Intraocular drug delivery systems targeting glaucomatous symptoms under clinical investigations (data accessed in February of 2023)
Drug delivered | Manufacturer | Product name | Main drug carrier | Route and designed duration | Investigated condition(s) | Phase | References and ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|---|
Bimatoprost | Allergan plc (Dublin, Ireland) | Durysta | PLGA (Novadur®) | Intracameral delivery; 4–6 months | OAG; OHT | Phase III (FDA approved) | [142, 195,196,197,198,199,200, 202] NCT04647214 NCT05338606 NCT03891446 |
Travoprost | Glaukos Corporation (San Clemente, CA, USA) | iDose | Titanium and a sustained release membrane | Intracameral delivery; Over 12 months | OAG; OHT | Phase III | NCT02754596 NCT03868124 |
Travoprost | Ocular Therapeutix Inc (Bedford, MA, USA) | OTX-TIC | Microparticles embedded hydrogel | Intracameral delivery; 4–6 months | OAG; OHT | Phase II | NCT04360174 NCT05335122 |
Latanoprost | PolyActiva Pty Ltd (Parkville, Australia) | PA5108 | Polytriazole hydrogel | Intracameral delivery; 6 months | OAG; OHT | Phase IIa | NCT03604328 NCT04060758 |
Travoprost | Envisia Therapeutics (Durham, NC, USA) | ENV515 | Polymers with PRINT® technology | Intracameral delivery; ND | OAG; OHT | Phase II | NCT02371746 |
CNTF | Neurotech Pharmaceuticals, Inc (Cumberland, RI, USA) | NT-501 | Polymer membrane (ECT platform) | Intravitreal delivery; ND | Glaucoma | Phase II | NCT01408472 NCT04577300 NCT02862938 |